Approval for generic version of Xeljanz enables immediate launch and strengthens Aurobindo’s U.S. portfolio with its 586th ANDA approval
Multi-target licensing agreement combines Stipple Bio’s epitope discovery platform with Lonza’s ADC technologies to develop targeted cancer treatments
Company expands injectable portfolio with therapeutically equivalent version of Vimpat®, targeting a market valued at approximately $15.2 million annually
Anbalagan has led end-to-end product development programs from concept to commercialization, with a strong focus on regulatory compliance, process scalability, and manufacturing readiness
Crucially, Lupin is the exclusive first-to-file applicant for this product and is eligible for 180-day generic drug exclusivity in the U.S. market
The approved product is the generic equivalent of Sutab® Tablets developed by Azurity Pharmaceuticals
A one-shot gene-editing cholesterol therapy could soon be a reality
AAV vectors are widely used in gene therapy for their strong therapeutic potential
Approved product is therapeutically equivalent to Synthroid of AbbVie and is indicated for the treatment of congenital or acquired hypothyroidism
The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon peptide platform
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
